Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction.

Ramos, F, ThГ©pot, S, Pleyer, L, Maurillo, L, Itzykson, R, Bargay, J, Stauder, R, Venditti, A, Seegers, V, MartГ­nez-Robles, V, Burgstaller, S, RГ©cher, C, DebГ©n, G, Gaidano, G, Gardin, C, Musto, P, Greil, R, SГЎnchez-Guijo, F, Fenaux, P. Leuk Res. 2015, 39(3): 296-306.

Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.

Wasle, I, Gamerith, G, Kocher, F, Mondello, P, Jaeger, T, Walder, A, Auberger, J, Melchardt, T, Linkesch, W, Fiegl, M, Mian, M. Ann Hematol. 2015, 94(4): 593-601.

Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy.

Sochalska, M, Tuzlak, S, Egle, A, Villunger, A. FEBS J. 2015, 282(5): 834-849.

The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.

Gutjahr, JC, Greil, R, Hartmann, TN. FRONT IMMUNOL. 2015, 6: 177.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.

Ludwig, H, Greil, R, Masszi, T, Spicka, I, Shpilberg, O, Hajek, R, Dmoszynska, A, Paiva, B, Vidriales, MB, Esteves, G, Stoppa, AM, Robinson, D, Chaturvedi, S, Ataman, O, Enny, C, Feng, H, van de Velde, H, Viterbo, L. Br J Haematol. 2015, 171(3): 3-54.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Fitzal, F, Filipits, M, Rudas, M, Greil, R, Dietze, O, Samonigg, H, Lax, S, Herz, W, Dubsky, P, Bartsch, R, Kronenwett, R, Gnant, M. Br J Cancer. 2015, 112(8): 1405-1410.

CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model.

Kocher, T, Asslaber, D, Zaborsky, N, Flenady, S, Denk, U, Reinthaler, P, Ablinger, M, Geisberger, R, Bauer, JW, Seiffert, M, Hartmann, TN, Greil, R, Egle, A, Hofbauer, JP. Leukemia. 2015, xx.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N. Mod Pathol. 2014 Jun,27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA Lancet Oncol. 2014 Jan,15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck

Keil, F, Selzer, E, Berghold, A, Reinisch, S, de Vries, A, Greil, R, Bachtiary, B, Tinchon, C, Anderhuber, W, Burian, M, Kasparek, AK, Elsasser, W, Kainz, H, Riedl, R, Kapp, K, Kopp, M, Kornek, G ONCOL RES TREAT. 2014, 37: 273-273. Ebenfalls in Pubmed gefunden: Eur J Cancer. 2013 Jan,49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14.